Skip to main content
. 2016 Sep 30;7(45):74152–74161. doi: 10.18632/oncotarget.12361

Table 1. Results of cytology, biopsy, immunostaining, and HPV genotyping and treatment of cervical GCC.

Case Age FIGO stage Cytology result Biopsy result Immunostaining result HPV genotype Treatment
p40 CEA ER PgR p16
1 38 IIB Carcinoma, type undetermined GCC Negative Negative Negative Negative Block positive HR HPV (type 18) detected CCRT
2 63 IIB Adenocarcinoma GCC Negative Negative Negative Negative Block positive HR HPV (type 16) detected CCRT
3 36 IIB Unsatisfactory/GCC* GCC Negative Negative Negative Negative Block positive HR HPV (type 31) detected CCRT
4 67 IIIB GCC GCC Negative Negative Negative Negative Block positive HR HPV (type 18) detected CCRT
5 37 IIB Poorly differentiated carcinoma GCC Negative Negative Focal positive Focal positive Block positive HR HPV (type 18) detected CCRT

Abbreviations: CCRT: concurrent chemoradiation therapy, CEA: carcinoembryonic antigen, ER: estrogen receptor; FIGO: International Federation of Gynecology and Obstetrics, GCC: glassy cell carcinoma, HPV: human papillomavirus, HR: high-risk, PgR: progesterone receptor;

*

At the time of recurrence